SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neuroscience

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scott_jiminez who started this subject2/10/2002 7:15:03 PM
From: tnsaf  Read Replies (1) of 278
 
B-Amyloid precursor protein transgenic mice that harbor diffuse A deposits but do not form plaques show increased ischemic vulnerability: Role of inflammation

[beta represented by 'B' in many places; jason]

Proc. Natl. Acad. Sci. USA, Vol. 99, Issue 3, 1610-1615, February 5, 2002

Milla Koistinaho*, Mikko I. Kettunen*, Gundars Goldsteins*, Riitta Keinänen*, Antero Salminen, Michael Ort,§, Jan Bures, David Liu¶, Risto A. Kauppinen*, Linda S. Higgins¶, and Jari Koistinaho*,,**
* A.I. Virtanen Institute for Molecular Sciences, Department of Neurology and Neuroscience, Department of Clinical Pathology of Kuopio University Hospital, University of Kuopio, P.O. Box 1627, FIN-70211, Kuopio, Finland; Institute of Physiology, Academy of Sciences of the Czech Republic, Videnska 1083, 142 20 Prague 4-Krc, Czech Republic; § Department of Psychiatry, First School of Medicine, Charles University, Ke Karlovu 11, 128 08 Prague 2, Czech Republic; and ¶ Scios Incorporated, Sunnyvale, CA 94085

B-amyloid (AB), derived form the B-amyloid precursor protein (APP), is important for the pathogenesis of Alzheimer's disease (AD), which is characterized by progressive decline of cognitive functions, formation of AB plaques and neurofibrillary tangles, and loss of neurons. However, introducing a human wild-type or mutant APP gene to rodent models of AD does not result in clear neurodegeneration, suggesting that contributory factors lowering the threshold of neuronal death may be present in AD. Because brain ischemia has recently been recognized to contribute to the pathogenesis of AD, we studied the effect of focal brain ischemia in 8- and 20-month-old mice overexpressing the 751-amino acid isoform of human APP. We found that APP751 mice have higher activity of p38 mitogen-activated protein kinase (p38 MAPK) in microglia, the main immune effector cells within the brain, and increased vulnerability to brain ischemia when compared with age-matched wild-type mice. These characteristics are associated with enhanced microglial activation and inflammation but not with altered regulation of cerebral blood flow, as assessed by MRI and laser Doppler flowmetry. Suppression of inflammation with aspirin or inhibition of p38 MAPK with a selective inhibitor, SD-282, abolishes the increased neuronal vulnerability in APP751 transgenic mice. SD-282 also suppresses the expression of inducible nitric-oxide synthase and the binding activity of activator protein 1. These findings elucidate molecular mechanisms of neuronal injury in AD and suggest that antiinflammatory compounds preventing activation of p38 MAPK in microglia may reduce neuronal vulnerability in AD.
------------------------------------------------------------
www.pnas.org/cgi/doi/10.1073/pnas.032670899
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext